Eli Lilly and Company's newly approved, Jaypirca (pirtobrutinib), may have the same target as BTK inhibitors already on the market, but it belongs to a different class in terms of how it will fit into the mantle cell lymphoma (MCL) treatment paradigm, and that is key to the company's commercial strategy around the drug.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?